Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miro-Cens: mirogabalin add-on to NSAIDs for neuropathic pain in cervical spondylotic radiculopathy
jRCTs031210629Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mirogabalin in Peripheral neuropathic pain (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in 1-week average upper limb pain NRS from baseline to week 12. Started Mar 2022; status: completed.
02
Drugs
mirogabalin
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on jRCTs031210629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210629.